Report of Foreign Issuer (6-k)
November 24 2017 - 8:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of November 2017
001-37353
(Commission File Number)
BIONDVAX PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in
its charter)
14 Einstein St.
Ness Ziona
Israel 74036
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Indicate by check mark whether by furnishing
the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
On November 20, 2017,
BiondVax Pharmaceuticals Ltd. (“BiondVax” or the “Company”) announced the signing of a clinical trial agreement
with the National Institute of Allergy and Infection Diseases of the U.S. National Institutes of Health for a Phase 2 clinical
trial in the U.S. using BiondVax’s product candidate, M-001. A copy of this press release is incorporated by reference herein as
Exhibit 99.1.
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
BiondVax Pharmaceuticals Ltd.
|
|
|
|
Date: November 23, 2017
|
By:
|
/s/ Ron Babecoff
|
|
|
Ron Babecoff
|
|
|
Chief Executive Officer
|
3
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2023 to Apr 2024